Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target
The Pharma Data
JANUARY 4, 2021
We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University. Barber’s work will give Kiromic a significant acceleration in the clinical development of its therapy platform and an even more significant advantage over its competitors. “We believe Prof.
Let's personalize your content